Editing Sumatriptan (section)

== Interactions ==
Concurrent use with other [[Triptan|triptans]] or ergot-containing medications (e.g., [[ergotamine]], [[dihydroergotamine]]) within 24 hours can result in additive [[vasoconstriction]].<ref name="DailyMed">{{Cite web |title=DailyMed - SUMATRIPTAN- sumatriptan succinate tablet tablet |url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2abc46d5-1810-469d-8d31-fafa7312421c |access-date=2024-05-03 |website=dailymed.nlm.nih.gov}}</ref><ref name="Medical_Letter_2023">{{Cite journal |title=Drugs for Migraine | journal = The Medical Letter on Drugs and Therapeutics | date = June 2023 | volume = 65 | issue = 678 | pages = 89–96| publisher = The Medical Letter Inc. | doi = 10.58347/tml.2023.1678a |url=https://secure.medicalletter.org/TML-article-1678a#:~:text=Subcutaneous%20sumatriptan%20is%20the%20most,in%20patients%20with%20vascular%20disease. |access-date=2024-05-03 |language=en}}</ref> Increased systemic exposure to sumatriptan can occur if used within 2 weeks after a [[monoamine oxidase inhibitor]] (MAOI).<ref name="Medical_Letter_2023" /> Cases of [[serotonin syndrome]] have been reported with co-administration of triptans and [[Serotonin reuptake inhibitor|serotonin reuptake inhibitors]].<ref name="DailyMed" />